Extended release opioid may help ease chronic neuropathic pain

An abstract presented at the American Academy of Pain Medicine meeting in San Antonio suggests that an extended-release oxymorphone (brand name: Opana) formula could be a reasonable treatment option for cancer patients needing long-term neuropathic pain management.

Chronic pain is divided into two types:
Nocioceptive: the pain moves along normal nerve pathways (described as dull or throbbing)
Neuropathic: the pain is caused by damage to the central nervous system (described as burning, shooting, radiating).

Traditionally, opioids are first-line therapy to treat nocioceptive pain, but are often third-line therapy for neuropathic pain. This small study, sponsored by Endo Pharmaceuticals (makers of Opana) suggests that extended-release oxymorphone may offer some benefit for patients suffering from chronic neuropathic pain.

By Ross Bonander

Source: Slatkin N, et al. Long-term management of neuropathic cancer pain with oxymorphone extended release: Results of a 1-year open-label extension trial AAPM 2010; Abstract 117.

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap